DiscGenics Collaboration Successfully Develops Allogeneic Therapy To Enable Efficient Manufacturing

DiscGenics is a biopharmaceutical company that develops regenerative cell-based therapies to alleviate low back pain and restore function in patients with degenerative diseases of the spine.

CHALLENGE

DiscGenics had established a novel process to generate cells for their allogeneic therapy, but knew they needed to improve the efficiency of the process as well as lower the cost of manufacturing. They wanted to develop a new technology to address this, but with a small team of ten employees they did not have the necessary expertise in-house. They also were not ready to invest in more equipment until they knew exactly what their process would require.

DiscGenics is building their own manufacturing facility and needed to limit their contract engagement to process development only. They were looking for scientists and engineers who could essentially work as an extension of their team in the areas where they had limited staff and resources.